Outcome of Board Meeting held on Thursday, 14th August, 2025
3BBLACKBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board approved unaudited standalone and consolidated financial results for Q1FY26 (quarter ended June 30, 2025), reviewed by statutory auditor Baheti & Co. with a clean Limited Review Report. Standalone revenue from operations grew ~16% YoY to Rs 2,035.71 lakhs (vs Rs 1,750.69 lakhs in Q1FY25), while profit after tax rose ~16% to Rs 1,246.04 lakhs (vs Rs 1,073.29 lakhs), translating to EPS of Rs 14.54. Consolidated revenue stood at Rs 2,223.46 lakhs with PAT of Rs 1,264.45 lakhs. Other expenses include a one-time Rs 84.06 lakhs M&A advisory and due diligence fee related to the acquisition of Coris Bioconcept SRL, Belgium. The Board also re-appointed Mr. Dhirendra Dubey as Chairman & MD for 5 years effective November 30, 2025, appointed Mr. Vivek Saihgal as Independent Director for 5 years, and re-appointed Sanjay Kasliwal & Associates as Cost Auditor for FY26.
Steady single-digit growth in revenue and profits with clean auditor review supports stable operations; the pending Coris Bioconcept Belgium acquisition could be a growth catalyst if completed, while director continuity provides management stability.